Boosted PI–based dual therapy provides similar safety and efficacy through 48 weeks compared with boosted PI–based triple therapy in treatment-naive patients including those with baseline HIV-1 RNA > 100,000 copies/mL.
In this retrospective analysis, patients with M184V or hepatitis C virus coinfection had a significantly higher probability of viral blips.
Rates of virologic rebound or virologic efficacy at Week 48 similar across subgroups of patients without history of DRV RAMs or virologic failure on DRV.
Independent of the NRTI backbone, a higher rate of patients receiving second-line DTG-based ART achieved HIV-1 RNA < 400 copies/mL.
Concomitant use of bisphosphonates and switch to TAF also associated with additional improvement in T-score at spine, but not at hip.
HIV-1 RNA < 100 copies/mL at Day 14 in 5/8 patients receiving dolutegravir vs 1/5 receiving standard-of-care efavirenz.
Overall efficacy and safety between the 2 INSTI-based, fixed-dose regimens comparable after 48 weeks.
Prioritizing public health interventions for these transmission networks, particularly young Hispanic MSM, may reduce further incidences of infections
Analysis suggests modifiable risk factors play a key role in increased morbidity and mortality following CKD diagnosis.
Following switch from ABC, patients had increases in collagen receptor glycoprotein VI expression and soluble receptor levels.